However, in cancer HepG2 cells, treatment with IBU-OAO or KET-OAO conjugates led rather to a reduction in the level of nuclear Nrf2 protein and binding to ARE sequence, suggesting the tendency to downregulation of this pathway. This evidence concerns the gene NFE2L2 and cancer.